Objective  Based on the retrospective analysis of follow-up information of outpatients with moderate and severe cancer pain in our hospital, the paper evaluates comprehensively the related factors affecting their survival, in order to provide professional pharmaceutical care.

Methods  Clinical data were collected from patients with moderate and severe cancer pain who had pharmaceutical fol-low-up records from January 2019 to September 2021. The follow-up information was retrospectively analyzed by the Kaplan-Meier method to evaluate the survival rate and survival time, and the survival curve was drawn and the related factors that affected the survival of outpatients with moderate and se-vere cancer pain were tested by Log-rank test for univariate analysis and Cox proportional hazards re-gression model.

Results  A total of 135 outpatients with moderate and severe cancer pain who met the inclusion and exclusion criteria were included in the study, including 88 males and 47 females, aging from 29 to 91, with the mean age of (64.96±11.01). During the study, 15 patients were lost and the fol-low-up rate was 88.9%. The mean overall survival time is (24.59±1.83) months, and the median surviv-al time is 18.00 (95%CI 13.5 to 22.5) months. The 1-year survival rate was 91.8%. The results of uni-variate and multivariate analysis show that chemoradiation and the combined use of NSAIDs and ox-ycodone hydrochloride sustained release tablets are independent protective factors affecting prognosis (P<0.05). During the follow-up period, 198 cases of adverse drug reactions were recorded after patients taking oxycodone hydrochloride sustained-release tablets. Among them, constipation (35.35%), vomit-ing (23.23%) and nausea (20.71%) were the main types. There were three cases of severe adverse reac-tions leading to admission, in which one was coma and two were tachypnea.

Conclusion  Chemoradia-tion and the combined use of NSAIDs and oxycodone hydrochloride sustained release tablets are favora-ble factors affecting the survival of outpatients with moderate and severe cancer pain. Pharmacists should pay close attention to chemoradiation and the combined drug use in pharmaceutical follow-up to provide professional pharmaceutical care.

1.Van den Beuken-van Everdingen MH, Hochstenbach LM, Joosten EA, et al. Update on prevalence of pain in patients with cancer: systematic review and meta-analysis[J]. J Pain Symptom Manage, 2016, 51(6): 1070-1090. DOI: 10.1016/j.jpainsymman.2015.12.340.

2.成沛玉, 邹惠美, 邱琼, 等. 癌性疼痛规范管理的现状与展望[J]. 中国医学创新, 2016, 13(8): 142-144. [Cheng PY, Zou HM, Qiu Q, et al. Current situation and prospect of standard management of cancer pain[J]. Medical Innovation of China, 2016, 13(8): 142-144.] DOI: 10.3969/j.issn.1674-4985.2016.08.040.

3.程乐. 阿片类药物对晚期中重度癌痛患者生存影响的临床研究[D]. 南宁: 广西医科大学, 2009. DOI: 10.7666/d.y1463054.

4.张凤玲, 陈凤菊, 刘美. 癌症疼痛患者院外疼痛管理现状调查及用药行为影响因素分析[J]. 护理实践与研究, 2013, 10(22): 4-7. [Zhang FL, Chen FJ, Liu M. Analysis the influence factors of drug use behavior of pain in patients with cancer pain management present situation[J]. Nursing Practice and Research, 2013, 10(22): 4-7.] DOI: 10.3969/j.issn.1672-9676.2013.22.002.

5.NCCN. NCCN Clinical Practice Guidelines in Oncology[R]. 2022: S1-57.

6.Ju SY, Ma SJ. High C-reactive protein to albumin ratio and the short-term survival prognosis within 30 days in terminal cancer patients receiving palliative care in a hospital setting: a retrospective analy-sis[J]. Medicine (Baltimore), 2020, 99(9): e19350. DOI: 10.1097/MD.0000000000019350.

7.宋健, 胡君娥, 胡欢欢, 等. 住院癌痛患者服药依从性现状及影响因素分析[J]. 护理管理杂志, 2017, 17(7): 463-465. [Song J, Hu JE, Hu HH, et al. The current statue and influencing factors of medication compliance among inpatients with cancer pain[J]. Journal of Nursing Administration, 2017, 17(7): 463-465.] DOI: 10.3969/j.issn.1671-315X.2017.07.003.

8.陈金凤. 生存分析在随访研究中的应用[J]. 实用老年医学, 2021, 35(9): 896. [Cheng JF. Application of survival analysis in follow-up studies[J]. Practical Geriatrics, 2021, 35(9): 896.] DOI: 10.3969/j.issn.1003-9198.2021.09.002.

9.Chen J, Lu XY, Wang WJ，et al. Impact of a clinical pharmacist-led guidance team on cancer pain therapy in China: a prospective multicenter cohort study[J]. J Pain Symptom Manage, 2014, 48(4): 500-509. DOI: 10.1016/j.jpainsymman.2013.10.015.

10.谢铮铮, 梁瑶, 杜朝阳,等. 临床药师干预对癌痛控制效果的随机对照研究[J]. 中国医院药学杂志, 2017, 37(6): 558-561. [Xie ZZ, Liang Y, Du CY, et al. Impact of clinical pharmacist intervention on cancer pain control: a randomized control study[J]. Chinese Journal of Hospital Pharmacy, 2017, 37(6): 558-561.] DOI: 10.13286/j.cnki.chinhosppharmacyj.2017.06.18.

11.熊承娟. 盐酸羟考酮缓释片与硫酸吗啡缓释片治疗中重度癌痛患者的临床效果比较[J]. 临床合理用药, 2021, 14(12): 83-85. [Xiong CJ. Comparison of clinical effects of oxycodone hydrochloride sustained release tablets and morphine sul-fate sustained release tablets in the treatment of moderate and severe cancer pain patients[J]. Chinese Journal of Clinical Rational Drug Use,  2021, 14(12): 83-85.] DOI: 10.15887 /j.cnki.13-1389 /r.2021.35.033.

12.李菲菲. 盐酸羟考酮缓释片与硫酸吗啡缓释片用于控制晚期胰腺癌癌痛的临床效果观察[J]. 中国现代药物应用, 2020, 14(24): 123-125. [Li FF. Clinical effect observation of oxycodone hydrochloride prolonged-release tablets and morphine sulfate sustained-release tablets for the control of pain in advanced pancreatic cancer[J]. Chin J Mod Drug Appl, 2020, 14(24): 123-125.] DOI:10.14164/j.cnki.cn11-5581/r.2020.24.056.

13.Liu MZ, Ma J, Li JD, et al. A comparison of the clinical effectiveness between low-dose strong opioids and non-steroidal anti-inflammatory drugs in the treatment of mild cancer pain: a randomized trial[J]. J Pain Res, 2021, 14: 3411-3419. DOI: 10.2147/JPR.S322893.

14.国家卫生健康委办公厅. 癌症疼痛诊疗规范(2018年版)[J]. 全科医学临床与教育, 2019, 17(1): 4-8. DOI: 10.13558/j.cnki.issn1672-3686.2019.01.002.

15.厉珊, 秦鹏, 沈洁. 盐酸羟考酮控释片联合塞来昔布治疗结直肠癌骨转移疼痛疗效及对患者心理状态和生活质量的影响[J]. 中国健康心理学杂志, 2018, 26(6): 894-897. [Li S, Qin P, Shen J. Effect of oxycodone hydrochloride controlled-release tablets combined with celecoxib on rectal cancer and bone metastasis pain.psychological status and life quality[J]. China Journal of Health Psychology, 2018, 26(6): 894-897.] DOI: 10.13342/j.cnki.cjhp.2018.06.027.

16.王菁. 中晚期胰腺癌患者生存预后临床观察及证候相关研究[D]. 北京: 北京中医药大学, 2021.

17.赵玉华. 药师全程化干预对门诊癌痛患者的疼痛影响研究[D]. 杭州: 浙江中医药大学, 2018.